Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | glucagon-like peptide 1 receptor | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Loa Loa (eye worm) | pigment dispersing factor receptor c | glucagon-like peptide 1 receptor | 463 aa | 388 aa | 25.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Onchocerca volvulus | 0.0074 | 1 | 0.5 | |
Chlamydia trachomatis | DNA topoisomerase I | 0.0074 | 1 | 0.5 |
Plasmodium falciparum | SWIB/MDM2 domain-containing protein | 0.0074 | 1 | 0.5 |
Brugia malayi | brahma associated protein 60 kDa | 0.0074 | 1 | 1 |
Loa Loa (eye worm) | SWIB/MDM2 domain-containing protein | 0.0074 | 1 | 1 |
Toxoplasma gondii | DNA topoisomerase domain-containing protein | 0.0074 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.006 | 0.5772 | 0.5772 |
Plasmodium vivax | hypothetical protein, conserved | 0.0074 | 1 | 0.5 |
Echinococcus multilocularis | SWI:SNF matrix associated | 0.0074 | 1 | 0.5 |
Echinococcus granulosus | SWI:SNF matrix associated | 0.0074 | 1 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0074 | 1 | 0.5 |
Brugia malayi | SWIB/MDM2 domain containing protein | 0.0074 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0074 | 1 | 1 |
Plasmodium vivax | SWIB/MDM2 domain-containing protein, putative | 0.0074 | 1 | 0.5 |
Echinococcus granulosus | Upstream activation factor subunit UAF30 | 0.0074 | 1 | 0.5 |
Chlamydia trachomatis | SWIB complex protein | 0.0074 | 1 | 0.5 |
Plasmodium falciparum | SWIB/MDM2 domain-containing protein | 0.0074 | 1 | 0.5 |
Echinococcus multilocularis | SWI:SNF matrix associated | 0.0074 | 1 | 0.5 |
Schistosoma mansoni | brg-1 associated factor | 0.0074 | 1 | 1 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.006 | 0.5772 | 0.5772 |
Echinococcus multilocularis | SWI:SNF matrix associated | 0.0074 | 1 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0074 | 1 | 1 |
Loa Loa (eye worm) | brahma associated protein | 0.0074 | 1 | 1 |
Echinococcus multilocularis | Upstream activation factor subunit UAF30 | 0.0074 | 1 | 0.5 |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.006 | 0.5772 | 0.5772 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.006 | 0.5772 | 0.5772 |
Schistosoma mansoni | hypothetical protein | 0.0074 | 1 | 1 |
Toxoplasma gondii | SWIB/MDM2 domain-containing protein | 0.0074 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
EC50 (functional) | 20 uM | PUBCHEM_BIOASSAY: High-throughput multiplex microsphere dose response for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, compounds from Cherry Pick 02. (Class of assay: confirmatory) | ChEMBL. | No reference |
EC50 (functional) | 20 uM | PUBCHEM_BIOASSAY: High-throughput multiplex microsphere dose response for inhibitors of toxin protease, specifically Lethal Factor protease, compounds from Cherry Pick 02. (Class of assay: confirmatory) | ChEMBL. | No reference |
EC50 (functional) | 20 uM | PubChem BioAssay. High-throughput multiplex microsphere dose response for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, compounds from Cherry Pick 02. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 10 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 31.6228 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488771] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.